Literature DB >> 23429599

Update on depression and age-related macular degeneration.

Robin J Casten1, Barry W Rovner.   

Abstract

PURPOSE OF REVIEW: This review updates the literature on depression in age-related macular degeneration (AMD). Treatment for AMD has been revolutionized since the 2004 review of depression and AMD. New data describing the prevalence of depression in AMD, as well as novel interventions for managing depression in AMD, are discussed. RECENT
FINDINGS: Depression continues to be prevalent in AMD and new information is available on the pathways by which impaired vision leads to depression. Strategies for the treatment of depression in patients with impaired vision have evolved.
SUMMARY: AMD is still a major risk factor for depression and people with activity restriction due to vision loss are at greatest risk. An integrated approach to depression management in older adults with impaired vision may be the best course of action.

Entities:  

Mesh:

Year:  2013        PMID: 23429599      PMCID: PMC5903583          DOI: 10.1097/ICU.0b013e32835f8e55

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  33 in total

1.  Self-management of age-related macular degeneration and quality of life: a randomized controlled trial.

Authors:  Barbara L Brody; Anne-Catherine Roch-Levecq; Anthony C Gamst; Kellie Maclean; Robert M Kaplan; Stuart I Brown
Journal:  Arch Ophthalmol       Date:  2002-11

Review 2.  Let us wake the nation on the treatment for age-related macular degeneration.

Authors:  Gary Brown; Melissa M Brown
Journal:  Curr Opin Ophthalmol       Date:  2010-05       Impact factor: 3.761

Review 3.  Evidence-based review of risk factors for geriatric depression and brief preventive interventions.

Authors:  Martin G Cole
Journal:  Psychiatr Clin North Am       Date:  2005-12

4.  Vision self-management for older adults: a randomised controlled trial.

Authors:  Sonya J Girdler; Duncan P Boldy; Satvinder S Dhaliwal; Margaret Crowley; Tanya L Packer
Journal:  Br J Ophthalmol       Date:  2010-02       Impact factor: 4.638

5.  Poor vision, functioning, and depressive symptoms: a test of the activity restriction model.

Authors:  Jamila Bookwala; Brendan Lawson
Journal:  Gerontologist       Date:  2011-07-06

6.  Anxiety and depression prevalence rates in age-related macular degeneration.

Authors:  Albert Augustin; José-Alain Sahel; Francesco Bandello; Roland Dardennes; Frédérique Maurel; Cristina Negrini; Klaus Hieke; Gilles Berdeaux
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

7.  Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

Authors:  B L Brody; A C Gamst; R A Williams; A R Smith; P W Lau; D Dolnak; M H Rapaport; R M Kaplan; S I Brown
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

8.  Effect of depression on vision function in age-related macular degeneration.

Authors:  Barry W Rovner; Robin J Casten; William S Tasman
Journal:  Arch Ophthalmol       Date:  2002-08

9.  Depression and mortality in the visually-impaired, community-dwelling, elderly population of Quebec.

Authors:  Marie Tournier; Yola Moride; Thierry Ducruet; Andriy Moshyk; Sophie Rochon
Journal:  Acta Ophthalmol       Date:  2007-09-21       Impact factor: 3.761

10.  The Depression in Visual Impairment Trial (DEPVIT): trial design and protocol.

Authors:  Tom H Margrain; Claire Nollett; Julia Shearn; Miles Stanford; Rhiannon Tudor Edwards; Barbara Ryan; Catey Bunce; Robin Casten; Mark T Hegel; Daniel J Smith
Journal:  BMC Psychiatry       Date:  2012-06-06       Impact factor: 3.630

View more
  27 in total

1.  Why visually impaired older adults often do not receive mental health services: the patient's perspective.

Authors:  Hilde P A van der Aa; Mirke Hoeben; Linda Rainey; Ger H M B van Rens; Hilde L Vreeken; Ruth M A van Nispen
Journal:  Qual Life Res       Date:  2014-11-15       Impact factor: 4.147

2.  [Requirements for low vision magnification aids in age-related macular degeneration: Data from the Tübingen low vision clinic (comparison of 2007-2011 with 1999-2005)].

Authors:  E K Altpeter; N X Nguyen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

3.  A chimeric Cfh transgene leads to increased retinal oxidative stress, inflammation, and accumulation of activated subretinal microglia in mice.

Authors:  Bogale Aredo; Tao Li; Xiao Chen; Kaiyan Zhang; Cynthia Xin-Zhao Wang; Darlene Gou; Biren Zhao; Yuguang He; Rafael L Ufret-Vincenty
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

4.  Age-Related Macular Degeneration: Epidemiology and Clinical Aspects.

Authors:  Tiarnán D L Keenan; Catherine A Cukras; Emily Y Chew
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

6.  Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Exp Eye Res       Date:  2015-09-12       Impact factor: 3.467

7.  Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial.

Authors:  Barry W Rovner; Robin J Casten; Mark T Hegel; Robert W Massof; Benjamin E Leiby; Allen C Ho; William S Tasman
Journal:  Ophthalmology       Date:  2014-07-09       Impact factor: 12.079

8.  Depressive and Anxiety Symptoms in Older Adults With Auditory, Vision, and Dual Sensory Impairment.

Authors:  Adam Simning; Meghan L Fox; Steven L Barnett; Silvia Sorensen; Yeates Conwell
Journal:  J Aging Health       Date:  2018-06-13

Review 9.  Anxiety and depression in patients with advanced macular degeneration: current perspectives.

Authors:  Verena R Cimarolli; Robin J Casten; Barry W Rovner; Vera Heyl; Silvia Sörensen; Amy Horowitz
Journal:  Clin Ophthalmol       Date:  2015-12-30

10.  Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration.

Authors:  Kerstin Birke; Erion Lipo; Marco T Birke; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.